The effectiveness of PD-1 monoclonal antibody in treating advanced lung cancer depends on the sensitivity of the cancer cells to the drug, with high sensitivity resulting in good results. It is not available for all advanced lung cancers. PD-1 monoclonal antibody is an immune checkpoint inhibitor for the treatment of primary lung cancer, including drugs such as karelizumab, navulizumab and pabrolizumab. Gene mutation status check is needed before using this drug in advanced lung cancer, if the therapeutic target of this drug has high expression level in tumor cells, the effect of using this drug is better. The treatment of advanced lung cancer is a comprehensive process, which requires a variety of means, including chemotherapy, palliative surgical treatment and so on. If there is a clear gene target, systemic treatment with immune checkpoint inhibitors such as karelizumab and other targeted drugs such as bevacizumab can be used concurrently and may achieve better results. In addition, when using immune checkpoint inhibitors such as karelizumab, navulizumab, pabolizumab, etc., fatigue, itchy rash, diarrhea, neutropenia, nausea, immune hepatitis, immune pneumonitis, and other discomforts may occur, and symptomatic treatment may be given, and if the adverse reactions are serious, the drug needs to be permanently discontinued. It is contraindicated for those who are allergic to the above drugs. Whether to use PD-1 monoclonal antibody to treat advanced lung cancer, it is recommended to consult oncologist.